Truist raised the firm’s price target on Edwards Lifesciences to $78 from $76 and keeps a Buy rating on the shares. The company’s Investor Day highlighted drivers to support 10% or more in revenue and earnings growth in FY25 and beyond through a combo of indication expansion and prod innovation across the company’s TAVR and TMTT franchises, the analyst tells investors in a research note. The 8%-10% FY24 constant currency revenue guide matched expectations, while a commitment to 10% in FY25 raised some eyebrows as a “high bar”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $77 from $75 at Baird
- Edwards Lifesciences price target lowered by $7 at Barclays, here’s why
- Edwards Lifesciences approves $1B of additional share repurchase authorization
- Edwards Lifesciences sees FY24 adjusted EPS $2.70-$2.80, consensus $2.80
- Edwards Lifesciences backs FY23 adjusted EPS view $2.47-$2.53, consensus $2.51
Questions or Comments about the article? Write to editor@tipranks.com